C11orf71 Inhibitors
C11orf71 inhibitors are a class of compounds that interfere with specific signaling pathways to indirectly decrease the functional activity of the C11orf71 protein. These inhibitors target various kinases and signaling molecules upstream of C11orf71, impacting its activity. For instance, PI3K inhibitors like LY294002 and Wortmannin obstruct the pathway leading to AKT activation. This, in turn, would abrogate downstream survival and growth signals, potentially leading to decreased C11orf71 activity if C11orf71 operates downstream of AKT. Similarly, mTOR inhibitors such as Rapamycin and PP242 can profoundly impact protein synthesis and cell growth pathways, which could translate to reduced C11orf71 activity if C11orf71 is implicated in these pathways.
Furthermore, MEK inhibitors such as U0126, PD98059,PD0325901, and GSK1120212 specifically target the MEK/ERK signaling cascade. The MEK/ERK pathway is a critical regulator of cell proliferation and survival, and if C11orf71 is a downstream effector within this pathway, its activity would be expected to decrease following MEK inhibition. The specificity of these compounds for MEK1/2 ensures that the impact on C11orf71 is due to the targeted suppression of ERK1/2 activation. In addition to the MEK/ERK pathway, p38 MAPK and JNK are part of the MAP kinase family, which responds to stress stimuli. Inhibitors such as SB203580 and SP600125 that target these kinases could attenuate the activation of transcription factors and other proteins involved in stress response and apoptosis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, LY294002 prevents the phosphorylation and activation of AKT, leading to a decrease in downstream survival and growth signals. If C11orf71 functions downstream of AKT, inhibition of PI3K would reduce C11orf71 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A steroidal metabolite that acts as a potent PI3K inhibitor. Wortmannin binds to the PI3K catalytic site, leading to the inhibition of AKT activation. Consequently, if C11orf71 activity is AKT-dependent, Wortmannin inhibition of PI3K would decrease C11orf71 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that binds to FKBP12 and the resulting complex inhibits mTORC1. This inhibition can suppress cell growth and protein synthesis pathways that may be essential for C11orf71 function, leading to its decreased activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, preventing the activation of ERK1/2. As ERK2 can regulate various proteins and transcription factors, the inhibition of MEK could lead to a decrease in C11orf71 activity if it is regulated by the ERK pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A synthetic compound that inhibits MEK, which in turn prevents the activation of ERK. If C11orf71 activity is contingent on the MEK/ERK pathway, PD98059 would result in decreased C11orf71 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A pyridinyl imidazole compound that selectively inhibits p38 MAPK. The inhibition of p38 MAPK might result in a decrease in C11orf71 activity if C11orf71 is regulated by p38 MAPK-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A reversible, ATP-competitive inhibitor of JNK1/2/3. By inhibiting JNK, SP600125 can suppress JNK pathway-dependent transcriptional events and other cellular processes, potentially leading to decreased C11orf71 activity. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
A selective mTOR inhibitor that inhibits both mTORC1 and mTORC2 complexes, unlike Rapamycin which primarily affects mTORC1. PP242's broad mTOR inhibition may more effectively decrease C11orf71 activity if it is linked to mTOR signaling. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
A PI3K inhibitor that impedes the PI3K-AKT pathway, leading to reduced cell proliferation and growth. By inhibiting PI3K, ZSTK474 may decrease the activity of C11orf71 if it is downstream of PI3K/AKT. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
A potent ATP-competitive mTOR inhibitor that affects both mTORC1 and mTORC2. AZD8055's comprehensive mTOR inhibition could lead to a more substantial decrease in C11orf71 activity if mTOR pathways regulate it. | ||||||